Quanterix Corp: management transactions · United States · SEC (Form 4)

About Quanterix Corp

Quanterix Corp. (NASDAQ: QTRX) is a U.S.-based life sciences company headquartered in Billerica, Massachusetts, United States. For international investors, the company sits at the intersection of biomarker science, diagnostics, and translational research. Founded in 2007, Quanterix built its franchise around its proprietary Simoa® platform, which is designed to detect and quantify proteins at extremely low concentrations in blood, serum, plasma, and other biofluids. That ultra-sensitivity is the core of its investment case and the basis of its differentiation versus more conventional measurement technologies. ([quanterix.com](https://www.quanterix.com/about-us/)) Quanterix’s business model is centered on instruments, consumables, assay kits, and related services. Its customer base spans academic research institutions, reference laboratories, biopharma companies, and diagnostic developers. The company’s products include Simoa analyzers and assay kits used in biomarker discovery, clinical research, and emerging diagnostic workflows. Management presents Quanterix as a “discovery-to-diagnostics” platform, with a particularly strong footprint in neurodegenerative disease research, where sensitive biomarker detection is critical for Alzheimer’s and related conditions. ([ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-expands-reach-ivd-and-large-reference-labs)) From a competitive standpoint, Quanterix is a specialized technology leader rather than a broad-based diagnostics conglomerate. Its moat comes from technical sensitivity, a meaningful installed base, and a large scientific validation record. The company states that its technology has been supported by more than 3,400 peer-reviewed publications, which helps reinforce credibility in the research community. Geographically, Quanterix sells directly in North America and several European countries, while also reaching customers globally through distribution partners. ([ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-releases-financial-results-second-quarter-2025)) A key recent strategic development is the 2025 acquisition of Akoya Biosciences, which expanded Quanterix into spatial biology and multiplex tissue imaging with single-cell resolution. The combined platform is intended to connect blood-based and tissue-based biology, broadening Quanterix’s addressable opportunities in neurology, immunology, and oncology. In 2025, the company also highlighted regulatory and commercial progress in markets such as China and South Korea, as well as new collaborations supporting Alzheimer’s testing infrastructure. ([ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-launches-novel-p-tau-205-and-p-tau-212-assays-advance?utm_source=openai)) For investors, Quanterix remains a specialized growth story listed on the NASDAQ in the United States, with exposure to research funding cycles and pharmaceutical spending, but with a differentiated platform positioned for precision medicine applications. ([ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-releases-financial-results-first-quarter-2025?utm_source=openai))